O Keefe Stevens Advisory Inc. Has $11.28 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

O Keefe Stevens Advisory Inc. grew its stake in Amgen Inc. (NASDAQ:AMGNGet Rating) by 2.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,643 shares of the medical research company’s stock after acquiring an additional 1,141 shares during the period. Amgen accounts for approximately 5.5% of O Keefe Stevens Advisory Inc.’s holdings, making the stock its 3rd largest position. O Keefe Stevens Advisory Inc.’s holdings in Amgen were worth $11,279,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in shares of Amgen in the 4th quarter valued at about $26,000. Norwood Financial Corp bought a new position in shares of Amgen in the 4th quarter valued at about $28,000. Industrial Alliance Investment Management Inc. bought a new position in shares of Amgen in the 4th quarter valued at about $31,000. Baltimore Washington Financial Advisors Inc. bought a new position in shares of Amgen in the 4th quarter valued at about $33,000. Finally, Econ Financial Services Corp bought a new position in Amgen during the fourth quarter worth about $34,000. Institutional investors own 79.01% of the company’s stock.

In related news, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the sale, the executive vice president now owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now directly owns 5,501 shares in the company, valued at approximately $1,375,250. The disclosure for this sale can be found here. 0.46% of the stock is owned by insiders.

A number of equities analysts recently commented on the company. Piper Sandler lifted their price target on Amgen from $255.00 to $260.00 in a report on Thursday, April 28th. Barclays lifted their price target on Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a report on Tuesday, April 12th. Mizuho lifted their price target on Amgen from $202.00 to $208.00 in a report on Tuesday, May 10th. BMO Capital Markets cut their price objective on shares of Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. Finally, Oppenheimer raised their price objective on shares of Amgen from $285.00 to $290.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 1st. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $242.57.

NASDAQ AMGN opened at $240.14 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. Amgen Inc. has a 1-year low of $198.64 and a 1-year high of $258.45. The company has a 50 day moving average of $244.62 and a 200-day moving average of $234.69. The company has a market cap of $128.28 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 2.05 and a beta of 0.57.

Amgen (NASDAQ:AMGNGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.22 by $0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The business had revenue of $6.24 billion during the quarter, compared to the consensus estimate of $6.09 billion. During the same period in the previous year, the business earned $3.70 earnings per share. On average, equities research analysts forecast that Amgen Inc. will post 17.44 earnings per share for the current year.

Amgen Company Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Recommended Stories

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.